{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:27:39Z","timestamp":1772832459768,"version":"3.50.1"},"reference-count":67,"publisher":"Nihon University School of Dentistry","issue":"1","funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23592730"],"award-info":[{"award-number":["23592730"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Oral Science","J Oral Sci"],"published-print":{"date-parts":[[2018]]},"DOI":"10.2334\/josnusd.17-0005","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T17:21:41Z","timestamp":1519924901000},"page":"37-44","source":"Crossref","is-referenced-by-count":12,"title":["Inhibition of 2-arachydonoylgycerol degradation attenuates orofacial neuropathic pain in trigeminal nerve-injured mice"],"prefix":"10.2334","volume":"60","author":[{"given":"Rantaro","family":"Kamimura","sequence":"first","affiliation":[{"name":"Division of Orthodontics, Department of Oral Biological Science,Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Z.","family":"Hossain","sequence":"additional","affiliation":[{"name":"Department of Oral Physiology, School of Dentistry, Matsumoto Dental University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumpei","family":"Unno","sequence":"additional","affiliation":[{"name":"Department of Oral Physiology, School of Dentistry, Matsumoto Dental University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Biology, Institute for Oral Science, Matsumoto Dental University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Masuda","sequence":"additional","affiliation":[{"name":"Institute for Oral Science, Matsumoto Dental University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Orthodontics, Department of Oral Biological Science,Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Otake","sequence":"additional","affiliation":[{"name":"Division of Orthodontics, Department of Oral Biological Science,Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Orthodontics, Department of Oral Biological Science,Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Oral Physiology, School of Dentistry, Matsumoto Dental University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1160","reference":[{"key":"1","unstructured":"1. Baron R (2006) Mechanisms of disease: neuropathic pain--a clinical perspective. Nat Clin Pract Neurol 2, 95-106."},{"key":"2","unstructured":"2. Sessle BJ (2000) Acute and chronic craniofacial pain: brainstem mechanisms of nociceptive transmission and neuroplasticity, and their clinical correlates. Crit Rev Oral Biol Med 11, 57-91."},{"key":"3","unstructured":"3. Gallagher RM, Rosenthal LJ (2008) Chronic pain and opiates: balancing pain control and risks in long-term opioid treatment. Arch Phys Med Rehabil 89, S77-82."},{"key":"4","unstructured":"4. Nightingale S (2012) The neuropathic pain market. Nat Rev Drug Discov 11, 101-102."},{"key":"5","unstructured":"5. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63, 569-611."},{"key":"6","unstructured":"6. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L et al. (2001) The role of central and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92, 91-100."},{"key":"7","unstructured":"7. Walker JM, Huang SM (2002) Cannabinoid analgesia. Pharmacol Ther 95, 127-135."},{"key":"8","unstructured":"8. Goya P, Jagerovic N, Hernandez-Folgado L, Martin MI (2003) Cannabinoids and neuropathic pain. Mini Rev Med Chem 3, 765-772."},{"key":"9","unstructured":"9. Costa B, Trovato AE, Colleoni M, Giagnoni G, Zarini E, Croci T (2005) Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 116, 52-61."},{"key":"10","unstructured":"10. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL (2011) Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther 90, 844-851."},{"key":"11","unstructured":"11. Lynch ME, Campbell F (2011) Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 72, 735-744."},{"key":"12","unstructured":"12. Thomas H (1996) A community survey of adverse effects of cannabis use. Drug Alcohol Depend 42, 201-207."},{"key":"13","unstructured":"13. Kalant H (2004) Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 28, 849-863."},{"key":"14","unstructured":"14. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4, 873-884."},{"key":"15","unstructured":"15. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A et al. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84-88."},{"key":"16","unstructured":"16. Pacher P, B\u00e1tkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58, 389-462."},{"key":"17","unstructured":"17. Jhaveri MD, Richardson D, Chapman V (2007) Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 152, 624-632."},{"key":"18","unstructured":"18. Alger BE, Kim J (2011) Supply and demand for endocannabinoids. Trends Neurosci 34, 304-315."},{"key":"19","unstructured":"19. Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ et al. (2006) Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148, 102-113."},{"key":"20","unstructured":"20. Russo R, Loverme J, La Rana G, Compton TR, Parrott J, Duranti A et al. (2007) The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3\u2019-carbamoylbiphenyl3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 322, 236-242."},{"key":"21","unstructured":"21. Desroches J, Guindon J, Lambert C, Beaulieu P (2008) Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol 155, 913-924."},{"key":"22","unstructured":"22. Kinsey SG, Long JZ, Cravatt BF, Lichtman AH (2010) Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms. J Pain 11, 1420-1428."},{"key":"23","unstructured":"23. Caprioli A, Coccurello R, Rapino C, Di Serio S, Di Tommaso M, Vertechy M et al. (2012) The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models. J Pharmacol Exp Ther 342, 188-195."},{"key":"24","unstructured":"24. Guindon J, Lai Y, Takacs SM, Bradshaw HB, Hohmann AG (2013) Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol Res 67, 94-109."},{"key":"25","unstructured":"25. Ignatowska-Jankowska BM, Ghosh S, Crowe MS, Kinsey SG, Niphakis MJ, Abdullah RA et al. (2014) In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol 171, 1392-1407."},{"key":"26","unstructured":"26. Zakir HM, Mostafeezur RM, Suzuki A, Hitomi S, Suzuki I, Maeda T et al. (2012) Expression of TRPV1 channels after nerve injury provides an essential delivery tool for neuropathic pain attenuation. PLoS One 7, e44023."},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Mostafeezur RM, Zakir HM, Yamada Y, Yamamura K, Iwata K, Sessle BJ et al. (2012) The effect of minocycline on the masticatory movements following the inferior alveolar nerve transection in freely moving rats. Mol Pain, doi: 10.1186\/1744-8069-8-27.","DOI":"10.1186\/1744-8069-8-27"},{"key":"28","unstructured":"28. Mostafeezur RM, Shinoda M, Unno S, Zakir HM, Takatsuji H, Takahashi K et al. (2014) Involvement of astroglial glutamate-glutamine shuttle in modulation of the jaw-opening reflex following infraorbital nerve injury. Eur J Neurosci 39, 2050-2059."},{"key":"29","unstructured":"29. Hossain MZ, Unno S, Ando H, Masuda Y, Kitagawa J (2017) Neuron-glia crosstalk and neuropathic pain: involvement in the modulation of motor activity in the orofacial region. Int J Mol Sci, doi: 10.3390\/ijms18102051."},{"key":"30","unstructured":"30. Hossain MZ, Shinoda M, Unno S, Ando H, Masuda Y, Iwata K et al. (2017) Involvement of microglia and astroglia in modulation of the orofacial motor functions in rats with neuropathic pain. J Oral Biosci 59, 17-22."},{"key":"31","unstructured":"31. Liang YC, Huang CC, Hsu KS (2007) The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. Neuropharmacology 53, 169-177."},{"key":"32","unstructured":"32. Zimmermann M (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16, 109-110."},{"key":"33","unstructured":"33. Imamura Y, Kawamoto H, Nakanishi O (1997) Characterization of heat-hyperalgesia in an experimental trigeminal neuropathy in rats. Exp Brain Res 116, 97-103."},{"key":"34","unstructured":"34. Kitagawa J, Takeda M, Suzuki I, Kadoi J, Tsuboi Y, Honda K et al. (2006) Mechanisms involved in modulation of trigeminal primary afferent activity in rats with peripheral mononeuropathy. Eur J Neurosci 24, 1976-1986."},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Ma F, Zhang L, Lyons D, Westlund KN (2012) Orofacial neuropathic pain mouse model induced by trigeminal inflammatory compression (TIC) of the infraorbital nerve. Mol Brain, doi: 10.1186\/1756-6606-5-44.","DOI":"10.1186\/1756-6606-5-44"},{"key":"36","unstructured":"36. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE et al. (2009) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5, 37-44."},{"key":"37","unstructured":"37. Iwata K, Imamura Y, Honda K, Shinoda M (2011) Physiological mechanisms of neuropathic pain: the orofacial region. Int Rev Neurobiol 97, 227-250."},{"key":"38","unstructured":"38. Katz PS, Sulzer JK, Impastato RA, Teng SX, Rogers EK, Molina PE (2015) Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury. J Neurotrauma 32, 297-306."},{"key":"39","unstructured":"39. Buczynski MW, Parsons LH (2010) Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls. Br J Pharmacol 160, 423-442."},{"key":"40","unstructured":"40. Saario SM, Salo OM, Nevalainen T, Poso A, Laitinen JT, J\u00e4rvinen T et al. (2005) Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. Chem Biol 12, 649-656."},{"key":"41","unstructured":"41. Burston JJ, Sim-Selley LJ, Harloe JP, Mahadevan A, Razdan RK, Selley DE et al. (2008) N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase. J Pharmacol Exp Ther 327, 546-553."},{"key":"42","unstructured":"42. Kinsey SG, Long JZ, O\u2019neal ST, Abdullah RA, Poklis JL, Boger DL et al. (2009) Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 330, 902-910."},{"key":"43","unstructured":"43. Guindon J, Guijarro A, Piomelli D, Hohmann AG (2011) Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol 163, 1464-1478."},{"key":"44","unstructured":"44. Ghosh S, Wise LE, Chen Y, Gujjar R, Mahadevan A, Cravatt BF et al. (2013) The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sci 92, 498-505."},{"key":"45","unstructured":"45. Spradley JM, Guindon J, Hohmann AG (2010) Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. Pharmacol Res 62, 249-258."},{"key":"46","unstructured":"46. Nomura H, Ogawa A, Tashiro A, Morimoto T, Hu JW, Iwata K (2002) Induction of Fos protein-like immunoreactivity in the trigeminal spinal nucleus caudalis and upper cervical cord following noxious and non-noxious mechanical stimulation of the whisker pad of the rat with an inferior alveolar nerve transection. Pain 95, 225-238."},{"key":"47","unstructured":"47. Noma N, Tsuboi Y, Kondo M, Matsumoto M, Sessle BJ, Kitagawa J et al. (2008) Organization of pERK-immunoreactive cells in trigeminal spinal nucleus caudalis and upper cervical cord following capsaicin injection into oral and craniofacial regions in rats. J Comp Neurol 507, 1428-1440."},{"key":"48","unstructured":"48. Saito K, Hitomi S, Suzuki I, Masuda Y, Kitagawa J, Tsuboi Y et al. (2008) Modulation of trigeminal spinal subnucleus caudalis neuronal activity following regeneration of transected inferior alveolar nerve in rats. J Neurophysiol 99, 2251-2263."},{"key":"49","doi-asserted-by":"publisher","unstructured":"49. Nakagawa K, Takeda M, Tsuboi Y, Kondo M, Kitagawa J, Matsumoto S et al. (2010) Alteration of primary afferent activity following inferior alveolar nerve transection in rats. Mol Pain, doi: 10.1186\/1744-8069-6-9.","DOI":"10.1186\/1744-8069-6-9"},{"key":"50","unstructured":"50. Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T, Iwase H et al. (2006) Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 126, 102-114."},{"key":"51","unstructured":"51. Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S et al. (2007) Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52, 415-422."},{"key":"52","doi-asserted-by":"publisher","unstructured":"52. Guasti L, Richardson D, Jhaveri M, Eldeeb K, Barrett D, Elphick MR et al. (2009) Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain. Mol Pain, doi: 10.1186\/1744-8069-5-35.","DOI":"10.1186\/1744-8069-5-35"},{"key":"53","unstructured":"53. Starowicz K, Makuch W, Osikowicz M, Piscitelli F, Petrosino S, Di Marzo V et al. (2012) Spinal anandamide produces analgesia in neuropathic rats: possible CB<sub>1<\/sub>- and TRPV1-mediated mechanisms. Neuropharmacology 62, 1746-1755."},{"key":"54","unstructured":"54. Wilkerson JL, Gentry KR, Dengler EC, Wallace JA, Kerwin AA, Armijo LM et al. (2012) Intrathecal cannabilactone CB<sub>2<\/sub>R agonist, AM1710, controls pathological pain and restores basal cytokine levels. Pain 153, 1091-1106."},{"key":"55","unstructured":"55. Kathuria S, Gaetani S, Fegley D, Vali\u00f1o F, Duranti A, Tontini A et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9, 76-81."},{"key":"56","unstructured":"56. Cravatt BF, Lichtman AH (2004) The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 61, 149-160."},{"key":"57","unstructured":"57. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL et al. (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311, 441-448."},{"key":"58","unstructured":"58. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG et al. (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13, 1113-1119."},{"key":"59","unstructured":"59. Ghosh S, Kinsey SG, Liu QS, Hruba L, McMahon LR, Grim TW et al. (2015) Full fatty acid amide hydrolase inhibition combined with partial monoacylglycerol lipase inhibition: augmented and sustained antinociceptive effects with reduced cannabimimetic side effects in mice. J Pharmacol Exp Ther 354, 111-120."},{"key":"60","unstructured":"60. Kinsey SG, Wise LE, Ramesh D, Abdullah R, Selley DE, Cravatt BF et al. (2013) Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther 345, 492-501."},{"key":"61","unstructured":"61. Lau BK, Vaughan CW (2014) Targeting the endogenous cannabinoid system to treat neuropathic pain. Front Pharmacol, doi: 10.3389\/fphar.2014.00028."},{"key":"62","unstructured":"62. Beltramo M, Piomelli D (2000) Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport 11, 1231-1235."},{"key":"63","unstructured":"63. Dinh TP, Kathuria S, Piomelli D (2004) RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol 66, 1260-1264."},{"key":"64","unstructured":"64. Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C (1997) cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem 272, 27218-27223."},{"key":"65","unstructured":"65. Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F et al. (2004) Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 20, 441-458."},{"key":"66","unstructured":"66. Stella N (2004) Cannabinoid signaling in glial cells. Glia 48, 267-277."},{"key":"67","unstructured":"67. Pihlaja R, Takkinen J, Eskola O, Vasara J, L\u00f3pez-Pic\u00f3n FR, Haaparanta-Solin M et al. (2015) Monoacylglycerol lipase inhibitor JZL184 reduces neuroinflammatory response in APdE9 mice and in adult mouse glial cells. J Neuroinflammation 12, 81."}],"container-title":["Journal of Oral Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/josnusd\/60\/1\/60_17-0005\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,24]],"date-time":"2018-03-24T01:36:49Z","timestamp":1521855409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/josnusd\/60\/1\/60_17-0005\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2334\/josnusd.17-0005","relation":{},"ISSN":["1343-4934","1880-4926"],"issn-type":[{"value":"1343-4934","type":"print"},{"value":"1880-4926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}